People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Progentos Therapeutics, Inc. | — | Pharma | Series C | $68.6M | $635.0M | 2024 |
Christopher Loose at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Loose on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Dan Janney | 1 | 4 |
| Cassidy Blundell | 1 | 2 |
| Aleks Radovic-Moreno | 1 | 1 |
| Dmitrij Hristodorov | 1 | 1 |
| Sanjay Magavi | 1 | 1 |
| Marc-Olivier Turgeon | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.